Human and zebrafish data corroborate gene x gene interactions in ameliorating Duchenne muscular dystrophy disease progression

A medRxiv preprint posted on 2 November 2026 reports evidence for gene-gene interaction effects on loss of ambulation in Duchenne muscular dystrophy, drawn from 419 patients in the United Dystrophinopathy Project whose primary DMD mutations are presumed to preclude production of residual dystrophin. The authors report strong evidence of interaction for 6 gene pairs, and tested one pair, MAN1A1 and ACTN3, in zebrafish, where they report an interaction effect with apparent rescue of muscle organisation to nearly wild-type levels. Claidex holds one recorded failure against DMD, ataluren-dmd-nonsense-mutation-duchenne-phase3-extension-sponsor-termination, a Phase 3 extension in nonsense mutation Duchenne muscular dystrophy that ended in a sponsor decision rather than on an efficacy readout, which is why this flag is graded MILD. The relevance is to endpoint variance rather than to target validity. If modifier genotypes at several loci shift the age at loss of ambulation independently of the primary dystrophin lesion, then ambulatory endpoints in genetically unstratified Duchenne cohorts carry variance the trial design does not see, and studies sized on an unadjusted natural history estimate will be underpowered for the effect they intend to detect. Nothing in this preprint speaks to whether ataluren works. It does suggest that the measurement used to settle that question is noisier than the design assumed.